Van ECK Associates Corp Grows Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Van ECK Associates Corp grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,210,428 shares of the company’s stock after purchasing an additional 35,192 shares during the quarter. Van ECK Associates Corp owned about 0.07% of Takeda Pharmaceutical worth $29,266,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc purchased a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB purchased a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets lifted its stake in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares in the last quarter. Smithfield Trust Co lifted its stake in Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Takeda Pharmaceutical during the 3rd quarter valued at approximately $52,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Down 0.6 %

TAK stock opened at $13.54 on Friday. The firm has a market cap of $43.07 billion, a PE ratio of 33.84, a PEG ratio of 0.24 and a beta of 0.51. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The firm’s 50 day moving average price is $13.27 and its 200-day moving average price is $13.88. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.